In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
Abundant Produce joins forces with Australia’s leading healthcare service provider
2 minute read
Abundant Produce (ASX:ABT) today revealed it has penned a sales, marketing and distribution agreement with HealthOne, which will commence in Australia.
This deal will see HealthOne representing Abundant Natural Health (ANH) products in Australian pharmacies servicing independent pharmacies and gift outlets.
HealthOne is Australia’s fastest growing healthcare commercial partner, with specialist national sales teams servicing all facets of the pharmacy channel, leveraging robust relationships with wholesalers, key banner groups, individual pharmacies and healthcare professionals.
It has been active in the Australian healthcare marketplace for over 15 years, representing market-leading companies and brands. Its multi‐dimensional approach encompasses brand strategy, marketing services, sales representation, merchandising, and staff education.
ABT CEO, Shanan Birkin, said: “Importantly, our agreement with HealthOne moves us from an online platform to a bricks-and-mortar presence with a partner that has the ability to penetrate the Australian market, using its in‐depth understanding of the intricacies of pharmacy product distribution.”
Birkin added: “This helps us to build on our objective of becoming a number-one player in the natural healthcare arena and the ethical brand of choice. We believe our 100% Australian grown, made and owned products are a game changer in our target markets.”
HealthOne managing director, Seona Wallace, commented: “We’re excited about representing these new innovative products, which are developed and produced locally by ANH in collaboration with the University of Sydney and the University of NSW.”
“Having science-based products of this calibre, particularly the new body and skin ranges, will be a great offering to the majors,” said Wallace.
It should be noted here that ABT remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.